Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.
Holst
Jens Juul
JJ
Department of Medical Physiology, University of Copenhagen, The Panum Institute, DK-2200 Copenhagen N, Denmark. holst@mfi.ku.dk
Deacon
Carolyn F
CF
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects* / Q000378:metabolism; D005934:Glucagon / Q000494:pharmacology / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011498:Protein Precursors / Q000494:pharmacology / Q000627:therapeutic use*; D006113:United Kingdom
D010446:Peptide Fragments; D011480:Protease Inhibitors; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D018819:Dipeptidyl Peptidase 4